Pneumology - Original Articles
4 August 2025

Histopathological assessment of thymoma based on the World Health Organization 2021 classification with emphasis on transcapsular invasion: experience from a tertiary care center

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
8
Views
1
Downloads

Authors

Histological classification and staging are crucial in the management and prognostication of thymoma. With different staging systems used, the significance of transcapsular invasion is debatable, especially in light of pathological tumor-node-metastasis (pTNM) staging (American Joint Committee on Cancer, 8th edition). The objective of this study was to analyze the histological subtypes, transcapsular invasion, and clinical outcome of thymoma with regard to the World Health Organization (WHO) 2021 classification. This retrospective study included all thymectomy specimens diagnosed as thymoma over a period of 10 years, from 2013 to 2023. Clinical details and histopathology slides were reviewed and histologically subtyped as per the WHO 2021 classification. Transcapsular invasion was assessed, and pTNM and modified Masoka staging were done. Descriptive statistics were used to summarize data. A total of 45 thymoma cases were identified; two with extensive infarction were excluded. The mean age was 46.5 years (range 25-68 years); in this study, there were 28 males and 15 females with a male-to-female ratio of 1.8:1. Myasthenia gravis was the presenting feature in 31 (72.9%) cases. B2 and B3 subtypes constituted half of the cases (22/43), with mixed patterns in 4 (9.3%). A total of 9 cases showed macroscopic invasion, 80% being the B3 subtype, and out of the 23 cases that showed transcapsular invasion, the three most common subtypes are listed here, with B3 being the most common, followed by AB and B2. Masaoka staging showed 11 (25.5%) stage I, 22 stage IIa (51.1), 6 stage IIb (13.9%), 1 stage III (2.3%), 2 stage IVa (4.6%), and 1 stage IVb (2.3%). Follow-up available in 38 out of 43 cases (range 4-127 months) showed recurrence in one case of the B3 subtype, stage IVb. None of the stage I and stage II (as per Masoka staging) patients had recurrence. The Masaoka stage is a widely used staging system where transcapsular invasion is an important parameter for upgrading stage I to stage II. However, in the present study, Masaoka stage I and II patients had no recurrence, questioning the significance of capsular invasion for staging. Accurate histological subtyping in thymoma is challenging but can be achieved by adherence to the morphological criteria of the WHO 2021 classification.

Altmetrics

Downloads

Download data is not yet available.

Citations

Weis CA, Yao X, Deng Y, et al. The impact of thymoma histotype on prognosis in a worldwide database. J Thorac Oncol 2015;10:367-72. DOI: https://doi.org/10.1097/JTO.0000000000000393
Hsu CH, Chan JK, Yin CH, et al. Trends in the incidence of thymoma, thymic carcinoma, and thymic neuroendocrine tumor in the United States. PLoS One 2019;14:e0227197. DOI: https://doi.org/10.1371/journal.pone.0227197
Marx A, Chan JKC, Chalabreysse L, et al. The 2021 WHO classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors? J Thorac Oncol 2022;17:200-13. DOI: https://doi.org/10.1016/j.jtho.2021.10.010
Marx A, Chan JKC, Detterbeck F, et al. Chapter 06: tumors of thymus. In: Thoracic tumors. WHO classification of tumours, 5th edition, volume 5. Available from: https://publications.iarc.fr/595.
Alothaimeen HS, Memon MA. Treatment outcome and prognostic factors of malignant thymoma - a single institution experience. Asian Pac J Cancer Prev 2020;21:653-61. DOI: https://doi.org/10.31557/APJCP.2020.21.3.653
Li J, Liu Y, Zhang X, et al. Prognostic factors for overall survival after surgical resection in patients with thymic epithelial tumors: a systematic review and meta-analysis. Medicine 2022;101:e30867. DOI: https://doi.org/10.1097/MD.0000000000030867
Detterbeck FC, Nicholson AG, Kondo K, et al. The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms. J Thorac Oncol 2011;6:S1710-6. DOI: https://doi.org/10.1097/JTO.0b013e31821e8cff
Nicholson AG, Detterbeck FC, Marino M, et al. The IASLC/ITMIG thymic epithelial tumors staging project: proposals for the T component for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol 2014;9:S73-80. DOI: https://doi.org/10.1097/JTO.0000000000000303
Detterbeck FC, Stratton K, Giroux D, et al. The IASLC/ITMIG thymic epithelial tumors staging project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol 2014;9:S65-72. DOI: https://doi.org/10.1097/JTO.0000000000000290
Filosso PL, Ruffini E, Lausi P, et al. Historical perspectives: The evolution of the thymic epithelial tumors staging system. Lung Cancer 2014;83:126-32. DOI: https://doi.org/10.1016/j.lungcan.2013.09.013
Markowiak T, Hofmann HS, Ried M. Classification and staging of thymoma. J Thorac Dis 2020;12:7607-12. DOI: https://doi.org/10.21037/jtd-2019-thym-01
Ahmad U. The eighth edition TNM stage classification for thymic tumors: what do I need to know? J Thorac Cardiovasc Surg 2021;161:1524-9. DOI: https://doi.org/10.1016/j.jtcvs.2020.10.131
Julka PK, Sharma DN, Mallick S, et al. Outcomes of thymoma treated with multimodality approach: a tertiary cancer center experience of 71 patients. Tumori 2017;103:572-6. DOI: https://doi.org/10.5301/tj.5000429
Sundaram C, Rajagopal P, Rakshak AD, et al. Clinicopathological study of thymoma--correlation of histologic subtype to myasthenia gravis and prognosis. Indian J Pathol Microbiol 2003;46:378-81.
Vaideeswar P, Padmanabhan A, Deshpande JR, et al. Thymoma: a pathological study of 50 cases. J Postgrad Med 2004;50:94-7.
Guleria P, Parshad R, Malik P, et al. Histotyping of Indian thymoma: a clinicopathologic study from north India. Indian J Med Res 2019;150:153-60. DOI: https://doi.org/10.4103/ijmr.IJMR_530_18
Detterbeck FC. Clinical value of the WHO classification system of thymoma. Ann Thorac Surg 2006;81:2328-34. DOI: https://doi.org/10.1016/j.athoracsur.2005.11.067
Jain RK, Mehta RJ, Henley JD, et al. WHO types A and AB thymoma: not always benign. Mod Pathol 2010;23:1641-9. DOI: https://doi.org/10.1038/modpathol.2010.172
Shamsuddin F, Khadilkar U, Saha D, et al. A clinicopathologic study of mediastinal lesions with special emphasis on thymoma. Int J Res Med Sci 2017;3:1902-10. DOI: https://doi.org/10.18203/2320-6012.ijrms20150299
Dhandapani K, Gandhi J, Timaniya S, et al. Histomorphological Spectrum and diagnostic challenges in thymic epithelial neoplasms with their prognostic significance: a case series of 33 cases at a regional cancer center in Western India. South Asian J Cancer 2022;13:191-202. DOI: https://doi.org/10.1055/s-0042-1757556
Ströbel P, Rosenwald A, Beyersdorf N, et al. Selective loss of regulatory T cells in thymoma. Ann Neurol 2004;56:901-4. DOI: https://doi.org/10.1002/ana.20340
Buckley C, Douek D, Newsom-Davis J, et al. Mature, long-lived CD4+ and CD8+ T cells are generated by the thymoma in myasthenia gravis. Ann Neurol 2001;50:64-72. DOI: https://doi.org/10.1002/ana.1017
Chen G, Marx A, Chen WH, et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer 2002;95:420-9. DOI: https://doi.org/10.1002/cncr.10665
Rena O, Papalia E, Maggi G, et al. World Health Organization histologic classification: An independent prognostic factor in resected thymoma. Lung Cancer. 2005;50:59-66. DOI: https://doi.org/10.1016/j.lungcan.2005.05.009
Kim DJ, Yang WI, Choi SS, et al. Prognostic and clinical relevance of the world health organization schema for the classification of thymic epithelial tumors. Chest 2005;127:755-61. DOI: https://doi.org/10.1378/chest.127.3.755
Suster S, Moran CA. Thymoma classification: current status and future trends. Am J Clin Pathol 2006;125:542-54. DOI: https://doi.org/10.1309/CAV8RNU5TKNACKNC
Ruangchira-urai R, Treetipsatit J. Update in thymoma for surgical pathologists. Asian Arch Pathol 2015;11:114-32.
Kondo K, Van Schil P, Detterbeck FC, et al.: The IASLC/ITMIG thymic epithelial tumors staging project: proposals for the N and M components for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol 2014;9:S81-7. DOI: https://doi.org/10.1097/JTO.0000000000000291
Gupta R, Marchevsky AM, McKenna RJ, et al. Evidence-Based pathology and the pathologic evaluation of thymoma: transcapsular invasion is not a significant prognostic feature. Arch Pathol Lab Med 2008;132:926-30. DOI: https://doi.org/10.5858/2008-132-926-EPATPE
Marchevsky AM, Gupta R, McKenna RJ, et al. Evidence based pathology and the pathologic evaluation of thymoma: the World Health Organization classification can be simplified into only 3 categories other than thymic carcinoma. Cancer 2008;112:2780-8. DOI: https://doi.org/10.1002/cncr.23492

Ethics approval

Ethical approval was taken from the Institutional Ethics Committee, St Johns Medical College and Hospital, Bangalore (IEC study ref no 276/2023).

How to Cite



“Histopathological Assessment of Thymoma Based on the World Health Organization 2021 Classification With Emphasis on Transcapsular Invasion: Experience from a Tertiary Care Center”. 2025. Monaldi Archives for Chest Disease, August. https://doi.org/10.4081/monaldi.2025.3354.